| ≤ 26 | ≥ 27 | P | Cramer’s V | ||
---|---|---|---|---|---|---|
N | % | N | % | |||
Place of residence | 13 | Â | 271 | Â | 0.966 | 0.002 |
Rural | 12 | 92.30 | 251 | 92.61 | Â | Â |
Urban | 1 | 07.70 | 20 | 7.39 | Â | Â |
Sex | 13 | Â | 271 | Â | 0.604 | 0.031 |
Male | 7 | 53.84 | 126 | 46.49 | Â | Â |
Female | 6 | 46.16 | 145 | 53.51 | Â | Â |
Marital status | 13 | Â | 271 | Â | 0.604 | 0.031 |
Single | 2 | 15.38 | 49 | 18.08 | Â | Â |
Married | 8 | 61.53 | 178 | 65.68 | Â | Â |
Widow(er) | 3 | 23.07 | 36 | 13.28 | Â | Â |
Divorced | 0 | 00.00 | 8 | 2.95 | Â | Â |
Level of education | 13 | Â | 271 | Â | 0.444 | 0.115 |
No education | 13 | 100 | 210 | 77.49 | Â | Â |
Primary | 0 | 00.00 | 35 | 12.91 | Â | Â |
College | 0 | 00.00 | 16 | 5.90 | Â | Â |
High School | 0 | 00.00 | 3 | 1.70 | Â | Â |
University | 0 | 00.00 | 7 | 2.58 | Â | Â |
Employment status | 13 | Â | 271 | Â | 0.533 | 0.067 |
Unemployed | 13 | 100 | 247 | 91.14 | Â | Â |
Retired | 0 | 00.00 | 12 | 4.42 | Â | Â |
Assets | 0 | 00.00 | 12 | 4.42 | Â | Â |
Social security coverage | 13 | Â | 271 | Â | 0.890 | 0.047 |
Insured | 12 | 92.30 | 232 | 85.60 | Â | Â |
Without insurance | 1 | 07.69 | 39 | 14.39 | Â | Â |
Type of health insurance | 13 | Â | 271 | Â | 0.433 | 0.098 |
CNOPS | 0 | 00.00 | 30 | 11.07 | Â | Â |
CNSS | 0 | 00.00 | 14 | 5.10 | Â | Â |
RAMED | 13 | 00.00 | 227 | 83.76 | Â | Â |
Treatment | 13 | Â | 271 | Â | 0.049* | 0.163 |
One OAD | 5 | 38.46 | 110 | 40.59 | Â | Â |
OAD + Insulin | 3 | 23.07 | 15 | 5.53 |  |  |
Two or more OADs | 1 | 07.69 | 66 | 24.35 | Â | Â |
Insulin alone | 4 | 30.76 | 80 | 29.52 | Â | Â |
Name of OAD taken | 13 | Â | 271 | Â | 0.202 | 0.160 |
Glimepiride 2Â mg | 0 | 00.00 | 18 | 6.64 | Â | Â |
Gliclazide 60Â mg | 0 | 00.00 | 42 | 15.49 | Â | Â |
Metformin 1000Â mg | 10 | 76.92 | 148 | 54.61 | Â | Â |
Gliclazide + Metformin | 0 | 00.00 | 33 | 12.17 |  |  |
Glimepiride + Metformin | 3 | 23.07 | 30 | 11.07 |  |  |
Associations | 13 | Â | 271 | Â | 0.090 | 0.151 |
Monotherapy | 6 | 46.15 | 179 | 66.05 | Â | Â |
Dual therapy | 2 | 15.38 | 83 | 30.62 | Â | Â |
Triple therapy and more | 2 | 15.38 | 9 | 3.32 | Â | Â |
Associated diseases | 13 | Â | 271 | Â | 0.003* | 0.266 |
AHT | 3 | 23.07 | 121 | 44.64 | Â | Â |
Dyslipidemia | 4 | 30.76 | 113 | 41.69 | Â | Â |
Other pathologies | 4 | 30.76 | 25 | 9.22 | Â | Â |
AHT + Dyslipidemia | 1 | 07.69 | 4 | 1.47 |  |  |
AHT + Others | 1 | 07.69 | 1 | 0.36 |  |  |
AHT + Dyslipidemia + Others | 0 | 00.00 | 7 | 2.58 |  |  |
Duration of disease | 13 | Â | 271 | Â | 0.998 | 0.043 |
Less than a year | 1 | 07.69 | 16 | 5.90 | Â | Â |
1 to 5 years | 5 | 38.46 | 88 | 32.47 | Â | Â |
6 to 10 years | 4 | 30.76 | 10 | 38.00 | Â | Â |
11 to 15 years | 1 | 07.69 | 25 | 9.22 | Â | Â |
16 to 20 years | 1 | 07.69 | 22 | 8.11 | Â | Â |
21 years and more | 1 | 07.69 | 17 | 6.27 | Â | Â |
Self-monitoring of blood glucose | 13 | Â | 271 | Â | 0.102 | 0.127 |
Yes | 4 | 30.76 | 167 | 61.62 | Â | Â |
No | 9 | 69.23 | 117 | 43.17 | Â | Â |
Information about diabetes | 13 | Â | 271 | Â | 0.127 | 0.091 |
Informed patients | 5 | 38.46 | 162 | 59.77 | Â | Â |
Uninformed patients | 8 | 61.5 | 109 | 40.22 | Â | Â |